<?xml version="1.0" encoding="UTF-8"?>
<p>Intravenous immunoglobulin (IVIg) may reduce SARS-CoV-2-induced inflammatory response by blocking FcR activation on monocytes. There are several clinical trials that will evaluate the efficacy and safety of IVIg therapy in patients with pneumonia caused by SARS-CoV-2. In a retrospective study of 58 COVID-19 patients, the use of IVIg within 48 h of admission increased in-hospital recovery and reduced 28-day mortality rate (
 <xref rid="B95" ref-type="bibr">95</xref>).
</p>
